Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Texas partnership enters fourth year
August 2016
SHARING OPTIONS:

SAN ANTONIO—July saw bioAffinity Technologies renew its collaborative agreement with The University of Texas Health Science Center at San Antonio for the research and development of novel cancer diagnostic and therapeutic agents leveraging bioAffinity's porphyrin-based technology platform. Dr. Alexander Persemlidis will lead the University's research team, with Dr. Vivienne Rebel leading the bioAffinity team.
 
“Our close working relationship and collaboration with the world-class researchers and scientists at The UT Health Science Center continue to move us that much closer to the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers,” said bioAffinity president and CEO Maria Zannes. “Dr. Pertsemlidis’ involvement provides bioAffinity with interesting and novel approaches to cancer therapeutics and a better understanding of the scientific underpinnings of the company’s diagnostic and drug delivery platform.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.